Drug Profile


Alternative Names: ADL5945; CB-5945; MK-2402; OpRA III

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Merck
  • Class Amides; Laxatives; Phenyl ethers; Pyrans; Pyrazines; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Constipation

Most Recent Events

  • 07 May 2015 Discontinued - Phase-III for Constipation in USA, Canada (PO)
  • 07 May 2015 Cubist Pharmaceuticals suspends a phase I trial for Constipation in USA (PO) (NCT02508740)
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top